Innovative Technology Micell Technologies has developed a proprietary supercritical fluid technology that enhances drug delivery systems, presenting an opportunity to partner with medical device companies seeking advanced treatment options for cardiovascular disease.

Global Expansion Having been acquired by Kossel Medical and promoted through international distribution channels like STENTYS, Micell is positioned for expansion in global markets, especially in regions where their CE-marked MiStent SES is authorized for sale.

Market Focus With a notable presence in interventional cardiology, Micell's flagship drug-eluting stent offers a compelling value proposition for healthcare providers and device manufacturers aiming to improve patient outcomes with innovative solutions.

Financial Opportunity Despite its small size with revenue between one and ten million dollars, Micell has secured funding of six million dollars, indicating investor confidence and potential for growth, making it an attractive partner for co-developing or integrating novel drug delivery technologies.

Partnership Potential The company's advanced supercritical fluid technology and focus on overcoming limitations of existing drug-eluting devices suggest opportunities for collaboration with larger firms looking to innovate or expand their product pipelines in the cardiovascular segment.